MabThera 1400 mg/11.7 mL (Rituximab) Subcutaneous Injection Solution

MabThera 1400 mg/11.7 mL (Rituximab) – Advanced Immunotherapy for Lymphoma and Autoimmune Diseases

MabThera (Rituximab) 1400 mg/11.7 mL is a subcutaneous injection used in the treatment of B-cell non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and autoimmune diseases such as rheumatoid arthritis (RA). Manufactured by Roche, this targeted therapy belongs to the class of monoclonal antibodies that selectively bind to the CD20 protein found on the surface of B lymphocytes, helping to eliminate abnormal or overactive B-cells.

Key Benefits of MabThera 1400 mg/11.7 mL:

✔ Fast Administration: Unlike traditional intravenous Rituximab infusions, this subcutaneous formulation allows for quicker administration, enhancing patient comfort and efficiency.
✔ Effective Targeted Therapy: MabThera works by specifically targeting CD20-positive B-cells, leading to their destruction while minimizing damage to healthy cells.
✔ Clinically Proven Efficacy: Extensively studied in clinical trials, Rituximab has been shown to improve progression-free survival rates in lymphoma and leukemia patients.
✔ Combination Therapy: Commonly prescribed alongside chemotherapy agents for enhanced therapeutic outcomes in hematological cancers.
✔ Autoimmune Disease Treatment: Approved for rheumatoid arthritis when combined with methotrexate, effectively reducing symptoms in patients unresponsive to conventional DMARDs.

Indications & Uses

MabThera 1400 mg/11.7 mL is prescribed for the following conditions:

• Non-Hodgkin’s Lymphoma (NHL) – A type of blood cancer affecting B lymphocytes.
• Chronic Lymphocytic Leukemia (CLL) – A slow-growing leukemia involving B-cell proliferation.
• Rheumatoid Arthritis (RA) – Used for patients with severe, treatment-resistant rheumatoid arthritis in combination with methotrexate.

How MabThera Works

MabThera (Rituximab) is a CD20-targeting monoclonal antibody that binds specifically to CD20-positive B-cells. Once attached, the drug triggers the immune system to destroy these abnormal cells, slowing disease progression and improving clinical outcomes.

Administration & Dosage

• MabThera 1400 mg is administered via subcutaneous injection, typically under medical supervision.
• The frequency and dosage depend on the patient’s condition, weight, and response to therapy.
• Patients should avoid live vaccines during treatment due to possible immune suppression.

Possible Side Effects

While MabThera is generally well-tolerated, some patients may experience:

• Infusion Reactions – Fever, chills, and allergic-like reactions may occur, especially during the first dose.
• Fatigue & Weakness – Common side effects in cancer patients.
• Low Blood Cell Counts – Risk of neutropenia or thrombocytopenia.
• Infections – Increased susceptibility to bacterial or viral infections.
• Rare Serious Effects – Progressive multifocal leukoencephalopathy (PML), an extremely rare but severe brain infection.

Precautions & Warnings

⚠ Not recommended during pregnancy and breastfeeding due to potential harm to the baby.
⚠ Patients should be screened for hepatitis B before starting therapy.
⚠ Live vaccines should be avoided while using MabThera.
⚠ Always consult a healthcare professional before initiating treatment.

Why Choose MabThera 1400 mg/11.7 mL?

• Efficient administration through subcutaneous injection.
• Reduced hospital time compared to IV infusion.
• Proven clinical efficacy in multiple hematological malignancies and autoimmune conditions.
• Manufactured by Roche, a globally trusted pharmaceutical company.

Conclusion

MabThera 1400 mg/11.7 mL offers a convenient and effective treatment option for patients suffering from B-cell cancers and autoimmune disorders. By directly targeting CD20-positive cells, it helps manage disease progression and improve survival rates.

🔹 Order now for safe and effective immunotherapy treatment!